Photo: CooperVision

GuruFocus.com

CooperVision’s global leadership in myopia control and management will be spotlighted next week at the 18^th annual International Myopia Conference, taking place in Rotterdam, the Netherlands. The meeting is expected to attract a record number of attendees, reflecting escalating interest in understanding and addressing the disease and its bearing on children’s short- and long-term vision and ocular health.

Among the highlights is a CooperVision symposium that will offer new insights into the treatment efficacy of the fastest growing eyes fit with MiSight^® 1 day contact lenses^*, derived from the world’s longest-running soft contact lens study among children. The international seven-year MiSight^® 1 day clinical trial has become the gold standard for evaluating myopia control effectiveness because of its robust design, multi-country enrollment, and extent of professionally published and peer-reviewed data. The findings will be presented by Paul Chamberlain, BSc (Hons), CooperVision Senior Director of Research Programs, and Arthur Bradley, PhD, CooperVision Research Fellow, on Monday, September 5, at 12:30 pm CEST.

Additional new research findings that span the company’s comprehensive range of optical interventions—including MiSight^® 1 day soft contact lenses, its ortho-k portfolio, and SightGlass Vision’s spectacle lenses incorporating Diffusion Optics Technology^™†, as well as related fitting tools—will be shared during multiple scientific papers and poster sessions.

“No one is doing more than CooperVision to advance the science and practice of myopia control and management. We are investing in every aspect of the category—elevating research and development, commercializing a broad product portfolio, educating eye care professionals (ECPs) and public officials, and raising awareness among parents,” said Chamberlain. “Our long-term commitment is already making a difference, with tens of thousands of ECPs and children benefitting from our trustworthy scientific findings, comprehensive evidence-based interventions, and knowledge sharing. It’s a privilege to help expand these impacts and encourage action during IMC 2022.”